The Genome Institute of Singapore (GIS) and Bioinformatics Institute (BII) of the Agency for Science, Technology and Research (A*STAR), as well as the National Heart Centre Singapore (NHCS), National University of Singapore (NUS), and pharmaceutical company Novo Nordisk, have signed an agreement to investigate the mechanisms underlying cardiovascular disease progression, particularly heart failure with preserved ejection fraction (HFpEF).
.
. Globally and in Singapore, heart disease is a leading cause of death. While HFpEF is a rising public health concern, particularly as a cause of significant debility in Singapore's ageing population, there are currently no treatments available to improve patient outcomes. Furthermore, Asians have a lower age of beginning of heart failure than Western populations. The goal of the research cooperation is to better understand the underlying biology of HFpEF patients in Asia, as well as to conduct comprehensive biomarker investigations that lead to patient segmentation based on pathologies, and to promote the development of heart failure treatments.
The Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), a translational cardiovascular research programme run by A*STAR that integrates efforts from fundamental, translational, and clinical scientists from different institutes across Singapore, is used in the study.
The initiative will specifically promote the integration of clinical imaging, molecular biology and clinical phenotypes, and the development of innovative heart failure medicines.
GIS and NHCS are using patient-specific cells in cellular investigations to analyze disease causes, while NUS does extra complicated proteome analysis on ATTRaCT patient biosamples. The BII serves as the data custodian for the ATTRaCT datasets that have been pooled from several universities, allowing project participants to access and analyze the various data kinds. This includes meeting the computing needs of both industry and academic researchers, as well as the administrative function of assuring adequate data governance.
Prof Roger Foo, ATTRaCT's Program Leader, Senior Group Leader of the Laboratory of Molecular Epigenomics and Chromatin Organization at A*STAR's GIS, and Director of the Cardiovascular Disease Translational Research Program at NUS Medicine, said: "We are honoured to be a part of this collaboration, which will draw on the multidisciplinary efforts of A*STAR and NUS scientists, as well as contributions from physicians from Singapore hospitals. The collaboration's findings will provide useful information about the genetic and cellular biomarkers linked to HFpEF, as well as support the development of new diagnostic tools and therapeutics for Asian patients with cardiovascular disease. HFpEF research is critically needed since it is a major public health concern for which there are currently no effective treatments."
Related Articles
The Importance of Automated LabTech Instruments in Research
The potential of pantethine against SARS-CoV-2 is being investigated.
Booster vaccination doses are critical for protection against all Omicron strains, according to research.
Prof Carolyn Lam, ATTRaCT's Founder and Senior Consultant in the Department of Cardiology at NHCS, said, "ATTRaCT described a novel lean diabetic phenotype of HFpEF, unique to our Asian region, through collaboration between premier clinical and scientific institutions in Singapore. We're now really excited to learn more about the disease and potentially develop new treatments for our patients."
Prof Mark Richards, Director of the Cardiovascular Research Institute at NUS, stated, "This collaboration enables for in-depth analysis of blood signs in heart failure. It opens the door to new ways of detecting and understanding this widespread and hazardous ailment, as well as novel tests and treatments that will help Singapore's health and economy."
"We are pleased about this new relationship," stated Dr. Karin Conde-Knape, Senior Vice President of Novo Nordisk. Novo Nordisk is always looking to collaborate with the best in the world, and we believe that working with leading research centres in Singapore will help us identify new therapeutic targets and biomarkers to address unmet medical needs in cardiovascular disease, which will benefit patients all over the world.
Posts
No comments:
Post a Comment